Global Cord Blood (NYSE:CO) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Global Cord Blood (NYSE:CO) in a research note published on Monday morning. The brokerage issued a strong-buy rating on the medical research company’s stock.

Global Cord Blood Stock Performance

CO opened at $1.05 on Monday. The stock has a market capitalization of $127.63 million, a price-to-earnings ratio of 1.64 and a beta of 0.16. The company has a fifty day moving average of $1.37 and a 200 day moving average of $1.40. Global Cord Blood has a fifty-two week low of $2.03 and a fifty-two week high of $5.50.

Global Cord Blood Company Profile

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.